300158 振东制药
已收盘 12-09 15:00:00
资讯
新帖
简况
振东制药(300158)披露增加股东大会临时提案,12月03日股价下跌2.09%
中金财经 · 12-03
振东制药(300158)披露增加股东大会临时提案,12月03日股价下跌2.09%
振东制药董事会薪酬与考核委员会实施细则获通过,强化治理与激励
中金财经 · 12-03
振东制药董事会薪酬与考核委员会实施细则获通过,强化治理与激励
振东制药:子公司为欧加隆提供米诺地尔搽剂制造服务
证券之星 · 12-02
振东制药:子公司为欧加隆提供米诺地尔搽剂制造服务
振东制药拟变更公司章程 取消监事会并调整治理结构
中金财经 · 12-02
振东制药拟变更公司章程 取消监事会并调整治理结构
振东制药(300158)股东山西振东健康产业集团有限公司质押1560万股,占总股本1.57%
证券之星 · 11-26
振东制药(300158)股东山西振东健康产业集团有限公司质押1560万股,占总股本1.57%
振东制药:中药材海外出口业务稳步推进
证券之星 · 11-25
振东制药:中药材海外出口业务稳步推进
振东制药(300158)披露关于回购股份注销完成暨股份变动的公告,11月24日股价上涨2.24%
证券之星 · 11-24
振东制药(300158)披露关于回购股份注销完成暨股份变动的公告,11月24日股价上涨2.24%
振东制药:公司无禽流感用药
证券之星 · 11-20
振东制药:公司无禽流感用药
股市必读:振东制药(300158)11月14日董秘有最新回复
证券之星 · 11-17
股市必读:振东制药(300158)11月14日董秘有最新回复
振东制药:公司将持续聚焦经营提升业绩
证券之星 · 11-14
振东制药:公司将持续聚焦经营提升业绩
振东制药:可通过米内网查询药品销售数据
证券之星 · 11-13
振东制药:可通过米内网查询药品销售数据
振东制药(300158)披露变更经营范围并修订《公司章程》议案获股东大会通过,11月12日股价上涨0.28%
证券之星 · 11-12
振东制药(300158)披露变更经营范围并修订《公司章程》议案获股东大会通过,11月12日股价上涨0.28%
振东制药(300158.SZ):中药1.1类新药星蒌承气颗粒IIa期临床试验首例受试者入组
智通财经 · 11-12
振东制药(300158.SZ):中药1.1类新药星蒌承气颗粒IIa期临床试验首例受试者入组
振东制药:暂无出口到日本的药品
证券之星 · 10-24
振东制药:暂无出口到日本的药品
振东制药:乳杆菌二联活菌胶囊Pre-NDA获CDE受理
证券之星 · 10-24
振东制药:乳杆菌二联活菌胶囊Pre-NDA获CDE受理
振东制药(300158)2025年三季报简析:净利润同比下降49.25%
证券之星 · 10-24
振东制药(300158)2025年三季报简析:净利润同比下降49.25%
股市必读:振东制药(300158)股东户数4.84万户,较上期增加4.89%
证券之星 · 10-24
股市必读:振东制药(300158)股东户数4.84万户,较上期增加4.89%
振东制药(300158.SZ)发布前三季度业绩,归母净利润2036.41万元,下降49.25%
智通财经 · 10-22
振东制药(300158.SZ)发布前三季度业绩,归母净利润2036.41万元,下降49.25%
股市必读:振东制药(300158)10月14日董秘有最新回复
证券之星 · 10-15
股市必读:振东制药(300158)10月14日董秘有最新回复
振东制药:星蒌承气颗粒正处于Ⅱ期临床试验阶段
证券之星 · 10-14
振东制药:星蒌承气颗粒正处于Ⅱ期临床试验阶段
加载更多
公司概况
公司名称:
山西振东制药股份有限公司
所属行业:
医药制造业
上市日期:
2011-01-07
主营业务:
山西振东制药股份有限公司的主营业务是肿瘤、皮科、消化、泌尿、心脑等仿制药、创新药的研发、生产、销售,以及种子种苗抚育、种植、加工、仓储、饮片于一体的中药材全产业链。公司的主要产品是复方苦参注射液、米诺地尔搽剂、生白颗粒、舒血宁注射液、西黄丸、独一味颗粒、复方胰酶散、大山楂丸。公司荣获“全国先进基层党组织”“全国脱贫攻坚先进集体”两个荣誉称号,荣获“第七届百姓安全用药”放心药奖、“山西省著名商标”等荣誉。
发行价格:
38.80
{"stockData":{"symbol":"300158","market":"SZ","secType":"STK","nameCN":"振东制药","latestPrice":6.36,"timestamp":1765263813000,"preClose":6.5,"halted":0,"volume":23082025,"delay":0,"changeRate":-0.0215,"floatShares":992000000,"shares":992000000,"eps":-1.3588,"marketStatus":"已收盘","change":-0.14,"latestTime":"12-09 15:00:00","open":6.5,"high":6.51,"low":6.35,"amount":148000000,"amplitude":0.0246,"askPrice":6.37,"askSize":2044,"bidPrice":6.36,"bidSize":1996,"shortable":0,"etf":0,"ttmEps":-1.3588,"tradingStatus":0,"nextMarketStatus":{"tag":"开盘","tradingStatus":2,"beginTime":1765330200000},"marketStatusCode":5,"adr":0,"adjPreClose":6.5,"symbolType":"stock","openAndCloseTimeList":[[1765243800000,1765251000000],[1765256400000,1765263600000]],"highLimit":7.15,"lowLimit":5.85,"ibTradeSell":false,"ibTradeBuySell":false,"totalEquity":992303056,"isCdr":false,"pbRate":1.76,"roa":"--","roe":"0.56%","epsLYR":-1.2977,"committee":0.491035,"marketValue":6311000000,"turnoverRate":0.0233,"status":1,"floatMarketCap":6307000000},"requestUrl":"/m/hq/s/300158","defaultTab":"news","newsList":[{"id":"2588014447","title":"振东制药(300158)披露增加股东大会临时提案,12月03日股价下跌2.09%","url":"https://stock-news.laohu8.com/highlight/detail?id=2588014447","media":"中金财经","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2588014447?lang=zh_cn&edition=full","pubTime":"2025-12-03 17:20","pubTimestamp":1764753640,"startTime":"0","endTime":"0","summary":"公司近日发布公告称,董事会决定于2025年12月18日召开2025年第二次临时股东大会,会议将审议包括第四期员工持股计划相关议案、变更注册资本暨修订公司章程、修订股东会议事规则等9项制度的议案。新增临时提案由控股股东山西振东健康产业集团有限公司于2025年12月2日提出,董事会同意将其提交股东大会审议。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://sc.stock.cnfol.com/gushiyaowen/20251203/31841798.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"zhongjincaijing_highlight","symbols":["300158","BK0186","BK0060","BK0239"],"gpt_icon":0},{"id":"2588067521","title":"振东制药董事会薪酬与考核委员会实施细则获通过,强化治理与激励","url":"https://stock-news.laohu8.com/highlight/detail?id=2588067521","media":"中金财经","labels":["executive"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2588067521?lang=zh_cn&edition=full","pubTime":"2025-12-03 08:00","pubTimestamp":1764720020,"startTime":"0","endTime":"0","summary":"中访网数据 山西振东制药股份有限公司董事会近日审议通过了《董事会薪酬与考核委员会实施细则》,旨在进一步完善公司治理结构,建立健全对董事及高级管理人员的薪酬与考核管理制度。根据细则,薪酬与考核委员会由三名董事组成,其中独立董事需占两名,主要负责制定并审查公司董事及高级管理人员的薪酬政策与方案,制定考核标准并进行绩效评价。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://sc.stock.cnfol.com/ggzixun/20251203/31840061.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"executive","news_rank":0,"length":0,"strategy_id":0,"source":"zhongjincaijing_highlight","symbols":["300158","BK0060","BK0239","BK0186"],"gpt_icon":0},{"id":"2588905355","title":"振东制药:子公司为欧加隆提供米诺地尔搽剂制造服务","url":"https://stock-news.laohu8.com/highlight/detail?id=2588905355","media":"证券之星","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2588905355?lang=zh_cn&edition=full","pubTime":"2025-12-02 20:53","pubTimestamp":1764679981,"startTime":"0","endTime":"0","summary":"证券之星消息,振东制药12月02日在投资者关系平台上答复投资者关心的问题。持有人是振东安欣!这品牌是美企业上市公司欧加隆公司的,旗下还有:内舒拿,妈富隆等等知名品牌,公司也是默沙东分拆独立出来的医疗健康公司!请问公司是否有与欧加隆合作?是否有开拓海外市场做准备?米诺地尔FDA认证是否批复?","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2025120200036954.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["BK0060","BK0239","300158","BK0186"],"gpt_icon":0},{"id":"2588058101","title":"振东制药拟变更公司章程 取消监事会并调整治理结构","url":"https://stock-news.laohu8.com/highlight/detail?id=2588058101","media":"中金财经","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2588058101?lang=zh_cn&edition=full","pubTime":"2025-12-02 20:30","pubTimestamp":1764678652,"startTime":"0","endTime":"0","summary":"中访网数据 山西振东制药股份有限公司于12月2日召开董事会及监事会会议,审议通过了关于变更注册资本及修订《公司章程》等一系列议案。更为关键的是,公司计划根据新《公司法》调整治理架构,拟不再设置监事会,其相关职权将由董事会下设的审计委员会行使。修订后的《公司章程》将删除所有涉及“监事”、“监事会”的条款及第七章“监事会”的全部内容,相关监事将自动解任。该议案尚需提交公司股东大会审议批准。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://sc.stock.cnfol.com/ggzixun/20251202/31839380.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"zhongjincaijing_highlight","symbols":["300158","BK0186","BK0239","BK0060"],"gpt_icon":0},{"id":"2586255178","title":"振东制药(300158)股东山西振东健康产业集团有限公司质押1560万股,占总股本1.57%","url":"https://stock-news.laohu8.com/highlight/detail?id=2586255178","media":"证券之星","labels":["shareholding"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2586255178?lang=zh_cn&edition=full","pubTime":"2025-11-26 18:40","pubTimestamp":1764153625,"startTime":"0","endTime":"0","summary":"证券之星消息,振东制药11月26日公开信息显示,股东山西振东健康产业集团有限公司向中国银行股份有限公司长治市分行合计质押1560.0万股,占总股本1.57%。质押详情见下表:截止本公告日,股东山西振东健康产业集团有限公司已累计质押股份1.61亿股,占其持股总数的53.19%。","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2025112600029034.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"shareholding","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["BK0239","BK0186","BK0060","300158"],"gpt_icon":0},{"id":"2586473392","title":"振东制药:中药材海外出口业务稳步推进","url":"https://stock-news.laohu8.com/highlight/detail?id=2586473392","media":"证券之星","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2586473392?lang=zh_cn&edition=full","pubTime":"2025-11-25 20:51","pubTimestamp":1764075076,"startTime":"0","endTime":"0","summary":"证券之星消息,振东制药(300158)11月24日在投资者关系平台上答复投资者关心的问题。投资者提问:董秘您好,请问贵司中药材海外出口业务近况如何?对未来有何计划?振东制药回复:尊敬的投资者您好!公司的相关业务正稳步推进。公司当前的中药材海外出口业务以山西道地中药材和基地大宗药材为基础,并正逐步加大中药材的出口销售比例。感谢您的关注!以上内容为证券之星据公开信息整理,由AI算法生成(网信算备310104345710301240019号),不构成投资建议。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2025112500036201.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["300158","BK0186","BK0060","BK0239"],"gpt_icon":0},{"id":"2585607914","title":"振东制药(300158)披露关于回购股份注销完成暨股份变动的公告,11月24日股价上涨2.24%","url":"https://stock-news.laohu8.com/highlight/detail?id=2585607914","media":"证券之星","labels":["buyback"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2585607914?lang=zh_cn&edition=full","pubTime":"2025-11-24 22:17","pubTimestamp":1763993826,"startTime":"0","endTime":"0","summary":"截至2025年11月24日收盘,振东制药报收于6.4元,较前一交易日上涨2.24%,最新总市值为63.51亿元。该股当日开盘6.26元,最高6.45元,最低6.25元,成交额达1.56亿元,换手率为2.48%。公司于近日发布公告称,山西振东制药股份有限公司于2025年11月21日完成回购股份注销手续,共计注销13,016,700股,占注销前总股本的1.29%。公司总股本由1,005,319,756股减少至992,303,056股。本次注销不影响公司财务状况和经营成果,股份分布仍符合上市条件。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2025112400035500.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"buyback","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["BK0060","BK0186","300158","BK0239"],"gpt_icon":0},{"id":"2584312051","title":"振东制药:公司无禽流感用药","url":"https://stock-news.laohu8.com/highlight/detail?id=2584312051","media":"证券之星","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2584312051?lang=zh_cn&edition=full","pubTime":"2025-11-20 20:52","pubTimestamp":1763643132,"startTime":"0","endTime":"0","summary":"证券之星消息,振东制药(300158)11月19日在投资者关系平台上答复投资者关心的问题。投资者提问:有没有禽流感用的药振东制药回复:尊敬的投资者您好!公司主营业务为肿瘤、皮科、消化、泌尿、心脑等仿制药、创新药的研发、生产、销售,以及种子种苗抚育、种植、加工、仓储、饮片于一体的中药材全产业链。公司无禽流感用药。感谢您的关注!以上内容为证券之星据公开信息整理,由AI算法生成(网信算备310104345710301240019号),不构成投资建议。","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2025112000035616.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["BK0060","300158","BK0239","BK0186"],"gpt_icon":0},{"id":"2584969868","title":"股市必读:振东制药(300158)11月14日董秘有最新回复","url":"https://stock-news.laohu8.com/highlight/detail?id=2584969868","media":"证券之星","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2584969868?lang=zh_cn&edition=full","pubTime":"2025-11-17 01:52","pubTimestamp":1763315534,"startTime":"0","endTime":"0","summary":"截至2025年11月14日收盘,振东制药报收于7.37元,上涨3.08%,换手率7.92%,成交量79.54万手,成交额5.87亿元。董秘最新回复投资者: 你好,董秘,同为创新药,贵公司和常山药业差距在哪儿?回购固然是好,但依然建议公司高层把资金用来收购好的标的企业,实现新的增长谢谢董秘: 答:尊敬的投资者您好!当日关注点来自交易信息汇总:11月14日主力资金净流出1760.73万元,显示主力资金持续离场。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2025111700000689.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["300158","BK0186","BK0239","BK0060"],"gpt_icon":0},{"id":"2583068725","title":"振东制药:公司将持续聚焦经营提升业绩","url":"https://stock-news.laohu8.com/highlight/detail?id=2583068725","media":"证券之星","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2583068725?lang=zh_cn&edition=full","pubTime":"2025-11-14 20:52","pubTimestamp":1763124731,"startTime":"0","endTime":"0","summary":"证券之星消息,振东制药11月14日在投资者关系平台上答复投资者关心的问题。公司为什么不采取积极措施提振股价?回购固然是好,但依然建议公司高层把资金用来收购好的标的企业,实现新的增长谢谢振东制药回复:答:尊敬的投资者您好!二级市场的股价波动受多重因素影响。公司将持续聚焦经营,通过优化产品矩阵、强化产品管线竞争力、加强渠道建设等多种举措提升公司业绩,以长期价值回报股东。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2025111400038559.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["BK0060","BK0186","BK0239","300158"],"gpt_icon":0},{"id":"2583540560","title":"振东制药:可通过米内网查询药品销售数据","url":"https://stock-news.laohu8.com/highlight/detail?id=2583540560","media":"证券之星","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2583540560?lang=zh_cn&edition=full","pubTime":"2025-11-13 20:48","pubTimestamp":1763038138,"startTime":"0","endTime":"0","summary":"证券之星消息,振东制药(300158)11月13日在投资者关系平台上答复投资者关心的问题。投资者提问:董秘您好!我想查询贵公司在国家组织药品集中采购中的中选药品的销售额这一数据,在哪里可以获取呢?振东制药回复:尊敬的投资者您好!您可通过米内网等第三方数据平台,查询到药品在全国三大终端(公立医院、零售药店、公立基层医疗)的市场销售数据。感谢您的关注!以上内容为证券之星据公开信息整理,由AI算法生成(网信算备310104345710301240019号),不构成投资建议。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2025111300039810.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["300158","BK0186","BK0060","BK0239"],"gpt_icon":0},{"id":"2582532489","title":"振东制药(300158)披露变更经营范围并修订《公司章程》议案获股东大会通过,11月12日股价上涨0.28%","url":"https://stock-news.laohu8.com/highlight/detail?id=2582532489","media":"证券之星","labels":["corporation"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2582532489?lang=zh_cn&edition=full","pubTime":"2025-11-12 17:35","pubTimestamp":1762940129,"startTime":"0","endTime":"0","summary":"截至2025年11月12日收盘,振东制药报收于7.04元,较前一交易日上涨0.28%,最新总市值为70.77亿元。近日,振东制药发布2025年第一次临时股东大会决议公告,公司于2025年11月11日召开2025年第一次临时股东大会,审议通过了《关于变更经营范围并修订<公司章程>的议案》。出席会议的股东及股东代表共606人,代表有表决权股份320,983,371股,占公司有表决权股份总数的32.3473%。表决结果显示,同意股份数占出席会议有效表决权的99.7510%,反对占0.1498%,弃权占0.0992%。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2025111200028741.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"corporation","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["BK0060","BK0186","300158","BK0239"],"gpt_icon":0},{"id":"2582239033","title":"振东制药(300158.SZ):中药1.1类新药星蒌承气颗粒IIa期临床试验首例受试者入组","url":"https://stock-news.laohu8.com/highlight/detail?id=2582239033","media":"智通财经","labels":["productRelease"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2582239033?lang=zh_cn&edition=full","pubTime":"2025-11-12 16:17","pubTimestamp":1762935453,"startTime":"0","endTime":"0","summary":"智通财经APP讯,振东制药(300158.SZ)发布公告,公司研发的中药1.1类新药星蒌承气颗粒正在开展IIa期临床试验,首例受试者已于近日成功入组给药。该药品功能主治:化痰通腑。用于缺血性脑卒中急性期痰热腑实证,症见半身不遂、偏身麻木、言语不利、头晕目眩,且兼有便秘便干、胸闷痰多、腹痛腹胀、恶心纳差、口干口苦、舌红苔黄腻、脉弦滑者。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://www.zhitongcaijing.com/content/detail/1368242.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"productRelease","news_rank":0,"length":0,"strategy_id":0,"source":"stock_zhitongcaijing","symbols":["BK0060","BK0186","300158","BK0239"],"gpt_icon":0},{"id":"2577519591","title":"振东制药:暂无出口到日本的药品","url":"https://stock-news.laohu8.com/highlight/detail?id=2577519591","media":"证券之星","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2577519591?lang=zh_cn&edition=full","pubTime":"2025-10-24 20:48","pubTimestamp":1761310099,"startTime":"0","endTime":"0","summary":"证券之星消息,振东制药(300158)10月23日在投资者关系平台上答复投资者关心的问题。投资者提问:300158振东制药,日本流感病毒爆发,贵公司有没有出口到日本的药物?振东制药回复:尊敬的投资者您好!公司暂无出口到日本的药品。感谢您的关注!以上内容为证券之星据公开信息整理,由AI算法生成(网信算备310104345710301240019号),不构成投资建议。","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2025102400040086.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["BK0060","BK0186","300158","BK0239"],"gpt_icon":0},{"id":"2577597519","title":"振东制药:乳杆菌二联活菌胶囊Pre-NDA获CDE受理","url":"https://stock-news.laohu8.com/highlight/detail?id=2577597519","media":"证券之星","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2577597519?lang=zh_cn&edition=full","pubTime":"2025-10-24 20:48","pubTimestamp":1761310098,"startTime":"0","endTime":"0","summary":"证券之星消息,振东制药(300158)10月23日在投资者关系平台上答复投资者关心的问题。投资者提问:请问用乳杆菌二联活菌胶囊的上市进度如何了?振东制药回复:尊敬的投资者您好!公司创新药乳杆菌二联活菌胶囊Pre-NDA申请已获CDE受理。后续尚需完成提交新药上市申请,经过审评、现场核查等严格的审批审评程序方可上市销售。公司将根据后续进展情况及时履行信息披露义务,敬请广大投资者谨慎决策,注意防范投资风险。感谢您的关注!以上内容为证券之星据公开信息整理,由AI算法生成(网信算备310104345710301240019号),不构成投资建议。","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2025102400040081.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["300158","BK0239","BK0060","BK0186"],"gpt_icon":0},{"id":"2577537984","title":"振东制药(300158)2025年三季报简析:净利润同比下降49.25%","url":"https://stock-news.laohu8.com/highlight/detail?id=2577537984","media":"证券之星","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2577537984?lang=zh_cn&edition=full","pubTime":"2025-10-24 06:04","pubTimestamp":1761257063,"startTime":"0","endTime":"0","summary":"据证券之星公开数据整理,近期振东制药发布2025年三季报。根据财报显示,振东制药净利润同比下降49.25%。截至本报告期末,公司营业总收入22.15亿元,同比下降2.42%,归母净利润2036.41万元,同比下降49.25%。按单季度数据看,第三季度营业总收入7.58亿元,同比下降0.69%,第三季度归母净利润1243.28万元,同比上升31.34%。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":["earning"],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2025102400004819.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-2","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["300158"],"gpt_icon":0},{"id":"2577587357","title":"股市必读:振东制药(300158)股东户数4.84万户,较上期增加4.89%","url":"https://stock-news.laohu8.com/highlight/detail?id=2577587357","media":"证券之星","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2577587357?lang=zh_cn&edition=full","pubTime":"2025-10-24 01:40","pubTimestamp":1761241215,"startTime":"0","endTime":"0","summary":"截至2025年10月23日收盘,振东制药报收于7.32元,上涨4.27%,换手率10.08%,成交量101.26万手,成交额7.53亿元。股本股东变化股东户数变动近日振东制药披露,截至2025年9月30日公司股东户数为4.84万户,较6月30日增加2256.0户,增幅为4.89%。户均持股数量由上期的2.18万股减少至2.08万股,户均持股市值为13.63万元。归属于上市公司股东的所有者权益:本报告期末为3,668,039,158.66元,比上年度末减少0.80%。","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2025102400001435.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["BK0186","BK0239","BK0060","300158"],"gpt_icon":0},{"id":"2577624443","title":"振东制药(300158.SZ)发布前三季度业绩,归母净利润2036.41万元,下降49.25%","url":"https://stock-news.laohu8.com/highlight/detail?id=2577624443","media":"智通财经","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2577624443?lang=zh_cn&edition=full","pubTime":"2025-10-22 20:54","pubTimestamp":1761137676,"startTime":"0","endTime":"0","summary":"智通财经APP讯,振东制药(300158.SZ)发布2025年三季度报告,该公司前三季度营业收入为22.15亿元,同比减少2.42%。归属于上市公司股东的净利润为2036.41万元,同比减少49.25%。归属于上市公司股东的扣除非经常性损益的净利润为50.75万元,同比增长101.67%。基本每股收益为0.0203元。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":["earning"],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://www.zhitongcaijing.com/content/detail/1358371.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-2","news_top_title":"振东制药(300158.SZ)发布前三季度业绩,归母净利润2036.41万元,下降49.25%","news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":"stock_zhitongcaijing","symbols":["300158"],"gpt_icon":0},{"id":"2575241117","title":"股市必读:振东制药(300158)10月14日董秘有最新回复","url":"https://stock-news.laohu8.com/highlight/detail?id=2575241117","media":"证券之星","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2575241117?lang=zh_cn&edition=full","pubTime":"2025-10-15 03:23","pubTimestamp":1760469788,"startTime":"0","endTime":"0","summary":"截至2025年10月14日收盘,振东制药报收于6.56元,下跌3.67%,换手率4.19%,成交量42.12万手,成交额2.81亿元。董秘最新回复投资者: 董秘你好,请问贵司截止2025年10月10日的股东人数是多少,目前贵司研发的药最新进展怎么样。公司的复方苦参注射液FDA临床申报资料已递交,目前处于FDA审评阶段,尚未获得临床试验许可。当日关注点来自交易信息汇总:10月14日主力与游资资金均呈净流出,散户资金净流入2008.98万元。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2025101500003453.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["BK0060","BK0239","300158","BK0186"],"gpt_icon":0},{"id":"2575021357","title":"振东制药:星蒌承气颗粒正处于Ⅱ期临床试验阶段","url":"https://stock-news.laohu8.com/highlight/detail?id=2575021357","media":"证券之星","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2575021357?lang=zh_cn&edition=full","pubTime":"2025-10-14 20:53","pubTimestamp":1760446420,"startTime":"0","endTime":"0","summary":"证券之星消息,振东制药10月14日在投资者关系平台上答复投资者关心的问题。投资者提问:董秘你好:这2两天在知名财经网站上看到,公司中药1.1创新药星篓承气颗粒颗粒已进入临床2期了,正在入组!公司中药1.1类创新药“星蒌承气颗粒”目前正处于Ⅱ期临床试验阶段。公司的复方苦参注射液FDA临床申报资料已递交,目前处于FDA审评阶段,尚未获得临床试验许可。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2025101400062465.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["300158","BK0239","BK0186","BK0060"],"gpt_icon":0}],"profile":{"ret":0,"serverTime":1765303431490,"stockEarnings":[{"period":"1week","weight":-0.0522},{"period":"1month","weight":-0.0592},{"period":"3month","weight":-0.1751},{"period":"6month","weight":0.3707},{"period":"1year","weight":0.2326},{"period":"ytd","weight":0.4722}],"compareEarnings":[{"period":"1week","weight":0.003},{"period":"1month","weight":-0.022},{"period":"3month","weight":0.0255},{"period":"6month","weight":0.149},{"period":"1year","weight":0.149},{"period":"ytd","weight":0.1664}],"compareStock":{"symbol":"000001.SH","name":"上证指数"},"companyName":"山西振东制药股份有限公司","boardCode":"AI0027","boardName":"医药制造业","stockholders":"48391人(较上一季度增加4.89%)","perCapita":"20493股","listingDate":"2011-01-07","address":"山西省长治市上党区光明南路振东科技园","registeredCapital":"99230万元","survey":" 山西振东制药股份有限公司的主营业务是肿瘤、皮科、消化、泌尿、心脑等仿制药、创新药的研发、生产、销售,以及种子种苗抚育、种植、加工、仓储、饮片于一体的中药材全产业链。公司的主要产品是复方苦参注射液、米诺地尔搽剂、生白颗粒、舒血宁注射液、西黄丸、独一味颗粒、复方胰酶散、大山楂丸。公司荣获“全国先进基层党组织”“全国脱贫攻坚先进集体”两个荣誉称号,荣获“第七届百姓安全用药”放心药奖、“山西省著名商标”等荣誉。","listedPrice":38.8},"APP":{"userAgent":"Mozilla/5.0 AppleWebKit/537.36 (KHTML, like Gecko; compatible; ClaudeBot/1.0; +claudebot@anthropic.com)","isDev":false,"isTTM":false,"deviceId":"web-server-community-laohu8-v3","version":"4.35.11","shortVersion":"4.35.11","platform":"web","vendor":"web","appName":"laohu8","isIOS":false,"isAndroid":false,"isTiger":false,"isTHS":false,"isWeiXin":false,"isWeiXinMini":false,"isWeiBo":false,"isQQ":false,"isBaiduSwan":false,"isBaiduBox":false,"isDingTalk":false,"isToutiao":false,"isOnePlus":false,"isHuaWei":false,"isXiaomi":false,"isXiaomiWebView":false,"isOppo":false,"isVivo":false,"isSamsung":false,"isMobile":false},"pagemeta":{"title":"振东制药(300158)_个股概要_股票价格_最新资讯_行情走势_历史数据","description":"美港股上老虎。老虎社区提供振东制药(300158)今日价格,行情走势,历史数据,股票概要及实时的新闻资讯,近期大事等重要参考决策数据。","keywords":"振东制药,300158,振东制药股票,振东制药股票老虎,振东制药股票老虎国际,振东制药行情,振东制药股票行情,振东制药股价,振东制药股市,振东制药股票价格,振东制药股票交易,振东制药股票购买,振东制药股票实时行情,购买美股,购买港股,港股开户,美股开户,美股交易,港股交易,开通美港股账户,老虎国际行情","social":{"og_title":"振东制药(300158)_个股概要_股票价格_最新资讯_行情走势_历史数据","og_description":"美港股上老虎。老虎社区提供振东制药(300158)今日价格,行情走势,历史数据,股票概要及实时的新闻资讯,近期大事等重要参考决策数据。","og_image":"https://static.tigerbbs.com/a0b84b8debbbce3b4440f7fdd5eed2e7"}}}